Eesti -
eesti -
Ravimiamet
estrofem õhukese polümeerikattega tablett
lex ano uab - östradiool - õhukese polümeerikattega tablett - 2mg 28tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosupressandid - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
kimmtrak
immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastilised ained - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
nulibry
tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - muud alimentary seedetrakti ja ainevahetust tooted, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
roctavian
biomarin international limited - valoctocogene roxaparvovec - antihemorraagilised ained - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
Eesti -
eesti -
Ravimiamet
brexin tablett
ideal trade links uab - piroksikaam - tablett - 20mg 10tk; 20mg 30tk; 20mg 20tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
pombiliti
amicus therapeutics europe limited - cipaglucosidase alfa - glükogeeni ladustamise ii tüüpi haigused - muud alimentary seedetrakti ja ainevahetust tooted, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).